This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2018 Nov 1;24(21):5485.

doi: 10.1158/1078-0432.CCR-18-3193.

Correction: MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR⁺/HER2^- Metastatic Breast Cancer

No authors listed

PMID: 30385657
DOI: 10.1158/1078-0432.CCR-18-3193

Published Erratum

Correction: MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR⁺/HER2^- Metastatic Breast Cancer

No authors listed. Clin Cancer Res. 2018.

. 2018 Nov 1;24(21):5485.

doi: 10.1158/1078-0432.CCR-18-3193.

PMID: 30385657
DOI: 10.1158/1078-0432.CCR-18-3193

No abstract available

PubMed Disclaimer

Erratum for

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR⁺/HER2^- Metastatic Breast Cancer.
Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J. Dickler MN, et al. Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22. Clin Cancer Res. 2017. PMID: 28533223 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal